SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of February, 2007
SkyePharma PLC
SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.
Form 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______
FOR IMMEDIATE RELEASE 8 FEBRUARY 2007
SkyePharma PLC
Announces Results of Shareholder Vote
LONDON, UK, 8 February 2007 - SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) announces the results of the voting by shareholders at the
Extraordinary General Meeting held earlier today.
All of the resolutions proposed were passed:
o Approval of the proposed sale of the Injectable Business to Blue Acquisition Corp (the "Disposal")
o Authorisation of the Directors to allot the new Ordinary Shares in connection with the Placing to raise £14.8 million net of
expenses
o Disapplication of statutory pre-emption rights in relation to the Placing
Good progress is being made with completing the various other conditions for the Disposal. The parties to the Disposal transaction
have jointly concluded that the transaction is not subject to the notice provisions of the Hart-Scott-Rodino Anti-Trust Improvements
Act of 1976 ("HSR") and that there are no HSR conditions applicable with respect to the Closing. The new Paul Capital agreements and
consents, which are subject to approval from Paul Capital's financial guaranty insurer and note holders, are expected to be finalised
shortly. It is expected that, once these agreements and consents are in place, the Disposal will be completed, and the Placing,
which is conditional upon the Disposal being completed, will take place on the stock market trading day immediately following that
completion. A further announcement will be made when the Disposal is completed.
Forthcoming results announcement
The announcement of the full year audited results for 2006 is scheduled to take place on 26 April 2007.
Frank Condella, SkyePharma's Chief Executive, said:
"I would like to thank shareholders for their support in passing these resolutions. Following the Disposal, SkyePharma will be well
funded and in a good position to build future value by further developing key products in the areas of oral and inhalation
technologies."
For further information please contact:
SkyePharma PLC +44 (0)20 7491 1777
Frank Condella, Chief Executive Officer
Ken Cunningham, Chief Operating Officer
Peter Grant, Finance Director
Buchanan Communications +44 (0)20 7466 5000
Tim Anderson / Mark Court / Rebecca Skye Dietrich
Trout Group (US)
Seth Lewis +(1) 617-583-1308
Notes for editors
About SkyePharma
SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use
and more effective drug formulations. The continuing business has nine approved products incorporating SkyePharma's technologies in
the areas of oral, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, visit
www.skyepharma.com.
These materials are not an offer for sale of securities in the United States. The securities in the placing have not been and will
not be registered under the US Securities Act of 1933 (the "Securities Act") and the securities may not be sold in the United States
absent registration or an exemption from registration under the Securities Act. The Company does not intend to register any portion
of such offering in the United States or to conduct a public offering of the ordinary shares in the United States.
The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any
sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to
registration, exemption from registration or qualification under the securities laws of any jurisdiction.
END
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SkyePharma PLC
By: /s/ John Murphy
Name: John Murphy
Title:
Company Secretary
Date: February 8, 2007